🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT05584566
Recruiting Not applicable

Ridge Augmentation Treatment Using OSSIX® BREEZE vs Jason®

NCT05584566 · tracked via the Priya Life Science UK tracker
Sponsor
Datum Dental LTD
Phase
Not applicable
Started
2022-12-01
Last updated
2024-10-16

Condition(s) studied

Ridge Augmentation

Investigational drug(s) / intervention(s)

OSSIX BreezeJason membrane

OSSIX Breeze: barrier membrane

Jason membrane: barrier membrane

Study summary

This is a prospective randomized controlled parallel trial. The aim of this study is to evaluate bone formation and soft tissue healing after 4 and 8 months in patients with ridge deficiencies in simultaneous implantation approach. The trial will compare a (sugar cross linked) - SCL pericardium membrane OSSIX® Breeze vs native pericardium membrane (Jason®).

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Males and females, age 18 and above. 2. General good health (ASA 1 and ASA 2). 3. Adults with buccal bone defect, who are in need of implant placement, and going through a guided bone regeneration treatment. 4. Patient needs 1-3 implants. 5. Good oral hygiene (full mouth plaque index \<25%). 6. Adequate control of inflammation (full mouth bleeding on probing \<25%). 7. Patient is willing to sign an informed consent and participate in the clinical study. 10 8. Patient is able to understand and comply with the study related procedures, such as exercising good oral hygiene and attending all follow-up examinations. Exclusion Criteria: 1. Physical status ASA III or ASA IV. 2. General contraindications for dental and/or surgical treatments. 3. Inflammatory and autoimmune disease of the oral cavity. 4. Patients with known collagen hypersensitivity. 5. Patients with sensitivity to porcine-derived materials. 6. Patients suffering from autoimmune diseases and connective tissue diseases, such as: systemic lupus erythematosus, dermatomyositis, etc. 7. Acute infection in the oral cavity or acute inflammation at the implantation site. 8. General diseases, where measures of stomatology, maxillo-facial surgery, implantology, periodontology, endodontology or other measures of oral surgery are contraindicated. 9. Disease of oral mucosa. 10. Uncontrolled periodontal disease 11. Concurrent or previous radiotherapy of head area. 12. Concurrent or previous immunosuppressant, bisphosphonate, or high-dose corticosteroid therapy. 13. Smoking (over 10 cigarettes a day). 14. Pregnant or lactating women. 15. Women of childbearing potential, who are not using a highly effective method of birth control. 16. Participation in another investigational device, drug, or biologics study within the last 24 weeks prior to study entry.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Hadassah Medical Center Jerusalem Israel Recruiting
Rabin Medical Center Petah Tikva Israel Recruiting
University of Birmingham Birmingham United Kingdom Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05584566 on ClinicalTrials.gov ↗ ← All trials in the UK